Published in N Engl J Med on December 07, 2006
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med (2013) 8.89
Regulation of chromatin by histone modifications. Cell Res (2011) 8.44
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med (2007) 8.18
JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature (2009) 4.60
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res (2010) 2.69
Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol (2009) 2.43
Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood (2008) 2.37
TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood (2011) 2.07
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest (2010) 1.93
A novel variant on chromosome 7q22.3 associated with mean platelet volume, counts, and function. Blood (2009) 1.85
Congenital and acquired polycythemias. Dtsch Arztebl Int (2008) 1.76
How I treat essential thrombocythemia. Blood (2010) 1.75
Therapeutic potential of JAK2 inhibitors. Hematology Am Soc Hematol Educ Program (2009) 1.74
Detection of MPLW515L/K mutations and determination of allele frequencies with a single-tube PCR assay. PLoS One (2014) 1.43
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood (2010) 1.42
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res (2008) 1.39
Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood (2007) 1.33
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood (2013) 1.30
Biology and significance of the JAK/STAT signalling pathways. Growth Factors (2012) 1.29
Mutations in the BRWD3 gene cause X-linked mental retardation associated with macrocephaly. Am J Hum Genet (2007) 1.26
LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease. Nat Cell Biol (2010) 1.25
Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? Curr Opin Hematol (2011) 1.18
Somatic and germline genetics at the JAK2 locus. Nat Genet (2009) 1.15
Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. Blood (2012) 1.13
Why target PIM1 for cancer diagnosis and treatment? Future Oncol (2010) 1.12
Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders. Blood (2007) 1.10
Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F. J Leukoc Biol (2009) 1.10
ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling. Blood (2009) 1.09
Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines. Am J Pathol (2008) 1.09
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica (2010) 1.08
JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica (2013) 1.08
Rethinking the diagnostic criteria of polycythemia vera. Leukemia (2013) 1.07
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. Leukemia (2013) 1.06
Inherited predisposition to myeloproliferative neoplasms. Ther Adv Hematol (2013) 1.06
Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms. Haematologica (2010) 1.01
Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. Cancer Discov (2016) 1.00
Reduced c-Myb activity compromises HSCs and leads to a myeloproliferation with a novel stem cell basis. EMBO J (2009) 1.00
Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3. Blood (2012) 1.00
The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica (2010) 0.99
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci U S A (2014) 0.96
Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis. Clin Cancer Res (2010) 0.95
Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity. Exp Hematol (2007) 0.94
Activation of JAK2-V617F by components of heterodimeric cytokine receptors. J Biol Chem (2010) 0.93
Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients. PLoS One (2010) 0.93
Loss of the proteostasis factor AIRAPL causes myeloid transformation by deregulating IGF-1 signaling. Nat Med (2015) 0.92
Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis. Mediators Inflamm (2015) 0.90
IDH1 R132H mutation is a rare event in myeloproliferative neoplasms as determined by a mutation specific antibody. Haematologica (2010) 0.90
JAK2V617F mutation in patients with splanchnic vein thrombosis. Dig Dis Sci (2009) 0.89
The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers. Ann Hematol (2007) 0.89
Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice. J Hematol Oncol (2014) 0.88
High resolution melting analysis: a rapid and accurate method to detect CALR mutations. PLoS One (2014) 0.87
Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia. Haematologica (2013) 0.87
The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow. Neoplasia (2011) 0.86
A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burden. PLoS One (2012) 0.86
MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives. Mediators Inflamm (2015) 0.86
Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood (2012) 0.85
Transcriptional profiling of whole blood identifies a unique 5-gene signature for myelofibrosis and imminent myelofibrosis transformation. PLoS One (2014) 0.85
Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi(®)). J Foot Ankle Surg (2013) 0.84
Signal transduction in the chronic leukemias: implications for targeted therapies. Curr Hematol Malig Rep (2013) 0.84
JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response. Proc Natl Acad Sci U S A (2014) 0.83
JAK2V617F mediates resistance to DNA damage-induced apoptosis by modulating FOXO3A localization and Bcl-xL deamidation. Oncogene (2015) 0.83
Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. Blood Cancer J (2011) 0.83
Myelofibrosis 2012: it's complicated. Ther Adv Hematol (2012) 0.83
Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. J Cell Mol Med (2009) 0.83
miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia. Blood Cancer J (2016) 0.82
Endogenous retrovirus induces leukemia in a xenograft mouse model for primary myelofibrosis. Proc Natl Acad Sci U S A (2014) 0.82
Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms. ACS Med Chem Lett (2015) 0.81
A potential role of ruxolitinib in leukemia. Expert Opin Investig Drugs (2011) 0.81
Budd-Chiari syndrome. United European Gastroenterol J (2015) 0.81
Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome. Leuk Res (2015) 0.80
A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis. Haematologica (2014) 0.80
Allelic imbalance in CALR somatic mutagenesis. Leukemia (2015) 0.80
The involvement of Galectins in the modulation of the JAK/STAT pathway in myeloproliferative neoplasia. Am J Blood Res (2012) 0.80
Improved diagnosis of the transition to JAK2 (V⁶¹⁷F) homozygosity: the key feature for predicting the evolution of myeloproliferative neoplasms. PLoS One (2014) 0.79
Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase. Haematologica (2010) 0.79
The role of growth differentiation factor 15 in the pathogenesis of primary myelofibrosis. Cancer Med (2015) 0.78
Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms. Rev Bras Hematol Hemoter (2011) 0.78
Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities. Leuk Res (2015) 0.77
Identification of a novel function of the clathrin-coated structure at the plasma membrane in facilitating GM-CSF receptor-mediated activation of JAK2. Cell Cycle (2012) 0.77
Calreticulin mutations in myeloproliferative neoplasms. Rambam Maimonides Med J (2014) 0.77
Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report. Afr Health Sci (2014) 0.77
JAK2 mutation and acute coronary syndrome complicated with stent thrombosis. Heart Vessels (2016) 0.76
Quantitative analyses of myelofibrosis by determining hydroxyproline. Stem Cell Investig (2015) 0.76
Spontaneous hemopericardium leading to cardiac tamponade in a patient with essential thrombocythemia. Cardiol Res Pract (2011) 0.76
[Myeloproliferative neoplasms: histopathological and molecular pathological diagnosis]. Pathologe (2012) 0.76
JAK V617F missense mutation is absent in pancreatic cancer. Gut (2007) 0.76
Targeting glutamine metabolism in myeloproliferative neoplasms. Blood Cells Mol Dis (2015) 0.76
Finding a needle in a haystack: whole genome sequencing and mutation discovery in murine models. J Clin Invest (2011) 0.76
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib. BMC Nephrol (2015) 0.75
Tales from the Jazz ASH: highlights from the 2013 American Society of Haematology meeting. Ecancermedicalscience (2014) 0.75
Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders. Leuk Res (2008) 0.75
Kinetics of del(7q) driven leukemogenesis in a patient with JAK2 V617F and TET2 mutated chronic myeloproliferative neoplasm. Leuk Res Rep (2013) 0.75
A 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic Myelofibrosis. PLoS One (2016) 0.75
Prognosis of Primary Myelofibrosis in the Genomic Era. Clin Lymphoma Myeloma Leuk (2016) 0.75
Screening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With Thrombocytosis. Ann Lab Med (2016) 0.75
Low neutrophil alkaline phosphatase score is a new aspect of calreticulin-mutated myeloproliferative neoplasms. Springerplus (2016) 0.75
Paradoxes in dermatology. Indian Dermatol Online J (2013) 0.75
A novel assay to detect calreticulin mutations in myeloproliferative neoplasms. Oncotarget (2016) 0.75
Low frequency of c-MPL gene mutations in Iranian patients with Philadelphia-negative myeloproliferative disorders. Iran J Ped Hematol Oncol (2015) 0.75
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
International network of cancer genome projects. Nature (2010) 20.35
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 18.59
Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med (2007) 8.18
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci U S A (2008) 7.22
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature (2009) 4.60
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med (2005) 3.92
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet (2005) 3.75
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet (2008) 3.69
Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood (2006) 2.98
JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood (2010) 2.83
Transcriptional regulation of the stem cell leukemia gene (SCL)--comparative analysis of five vertebrate SCL loci. Genome Res (2002) 2.77
Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood (2009) 2.77
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood (2008) 2.55
Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol (2009) 2.43
Establishing the transcriptional programme for blood: the SCL stem cell enhancer is regulated by a multiprotein complex containing Ets and GATA factors. EMBO J (2002) 2.40
Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol (2010) 2.32
Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood (2004) 2.30
Genome-wide analysis of simultaneous GATA1/2, RUNX1, FLI1, and SCL binding in megakaryocytes identifies hematopoietic regulators. Dev Cell (2011) 2.30
Gata2, Fli1, and Scl form a recursively wired gene-regulatory circuit during early hematopoietic development. Proc Natl Acad Sci U S A (2007) 2.15
Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood (2004) 2.11
Identification of endoglin as a functional marker that defines long-term repopulating hematopoietic stem cells. Proc Natl Acad Sci U S A (2002) 2.08
Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood (2006) 2.08
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood (2005) 1.92
The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood (2005) 1.91
The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Haematologica (2007) 1.83
Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion. PLoS Biol (2013) 1.82
Analysis of multiple genomic sequence alignments: a web resource, online tools, and lessons learned from analysis of mammalian SCL loci. Genome Res (2004) 1.80
Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell (2010) 1.78
How I treat essential thrombocythemia. Blood (2010) 1.75
DNA damage-induced Bcl-xL deamidation is mediated by NHE-1 antiport regulated intracellular pH. PLoS Biol (2007) 1.66
Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis. Blood (2008) 1.59
In vivo fate-tracing studies using the Scl stem cell enhancer: embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis. Blood (2004) 1.58
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood (2011) 1.56
Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood (2003) 1.54
Janus kinase deregulation in leukemia and lymphoma. Immunity (2012) 1.52
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood (2012) 1.52
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood (2007) 1.51
Genome-wide identification of cis-regulatory sequences controlling blood and endothelial development. Hum Mol Genet (2005) 1.43
Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. Br J Haematol (2007) 1.42
A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell (2013) 1.37
The SCL transcriptional network and BMP signaling pathway interact to regulate RUNX1 activity. Proc Natl Acad Sci U S A (2007) 1.36
The paralogous hematopoietic regulators Lyl1 and Scl are coregulated by Ets and GATA factors, but Lyl1 cannot rescue the early Scl-/- phenotype. Blood (2006) 1.35
The transcription factors Scl and Lmo2 act together during development of the hemangioblast in zebrafish. Blood (2006) 1.34
Endoglin expression in the endothelium is regulated by Fli-1, Erg, and Elf-1 acting on the promoter and a -8-kb enhancer. Blood (2006) 1.32
Fli1, Elf1, and Ets1 regulate the proximal promoter of the LMO2 gene in endothelial cells. Blood (2005) 1.26
LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease. Nat Cell Biol (2010) 1.25
Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. Br J Haematol (2012) 1.23
The scl +18/19 stem cell enhancer is not required for hematopoiesis: identification of a 5' bifunctional hematopoietic-endothelial enhancer bound by Fli-1 and Elf-1. Mol Cell Biol (2004) 1.22
Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia. Br J Haematol (2003) 1.20
JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood (2013) 1.18
Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica (2008) 1.18
Comparative and functional analyses of LYL1 loci establish marsupial sequences as a model for phylogenetic footprinting. Genomics (2003) 1.17
The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood (2010) 1.16
Identifying gene regulatory elements by genomic microarray mapping of DNaseI hypersensitive sites. Genome Res (2006) 1.13
Imprinting of the human L3MBTL gene, a polycomb family member located in a region of chromosome 20 deleted in human myeloid malignancies. Proc Natl Acad Sci U S A (2004) 1.11
Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood (2003) 1.10
ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling. Blood (2009) 1.09
Analyses of the extent of shared synteny and conserved gene orders between the genome of Fugu rubripes and human 20q. Genome Res (2002) 1.09
Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. Br J Haematol (2009) 1.09
Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Br J Haematol (2010) 1.08
Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. Br J Haematol (2006) 1.07
Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia. Br J Haematol (2014) 1.05
Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. N Engl J Med (2008) 1.04
CALR mutations in myeloproliferative neoplasms: hidden behind the reticulum. Am J Hematol (2014) 1.03
Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms. Blood (2011) 1.03
Real-time PCR mapping of DNaseI-hypersensitive sites using a novel ligation-mediated amplification technique. Nucleic Acids Res (2007) 1.03
Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. Haematologica (2008) 1.00
Guideline for the diagnosis and management of myelofibrosis. Br J Haematol (2012) 0.99
Mouse models of myeloproliferative neoplasms: JAK of all grades. Dis Model Mech (2011) 0.98
AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders. Br J Haematol (2010) 0.97
Management of polycythemia vera and essential thrombocythemia. Hematology Am Soc Hematol Educ Program (2005) 0.96
Transgenic analysis of the stem cell leukemia +19 stem cell enhancer in adult and embryonic hematopoietic and endothelial cells. Stem Cells (2005) 0.96
Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms. Blood (2011) 0.95
Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood (2003) 0.95
Three distinct patterns of histone H3Y41 phosphorylation mark active genes. Cell Rep (2012) 0.95
Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders. Methods Mol Med (2006) 0.94
A novel mode of enhancer evolution: the Tal1 stem cell enhancer recruited a MIR element to specifically boost its activity. Genome Res (2008) 0.94
The incidence of the JAK2 V617F mutation in patients with idiopathic erythrocytosis. Haematologica (2006) 0.94
Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. Br J Haematol (2014) 0.94
Pathogenesis and management of essential thrombocythemia. Hematology Am Soc Hematol Educ Program (2009) 0.93
Independently acquired biallelic JAK2 mutations are present in a minority of patients with essential thrombocythemia. Blood (2010) 0.92
Characterization of the imprinted polycomb gene L3MBTL, a candidate 20q tumour suppressor gene, in patients with myeloid malignancies. Br J Haematol (2004) 0.91
Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera. Br J Haematol (2007) 0.91
Manipulation of mouse hematopoietic progenitors by specific retroviral infection. J Biol Chem (2003) 0.91
cis-Regulatory remodeling of the SCL locus during vertebrate evolution. Mol Cell Biol (2010) 0.90
SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases. Haematologica (2009) 0.89
Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia. Haematologica (2013) 0.87
L3mbtl, the mouse orthologue of the imprinted L3MBTL, displays a complex pattern of alternative splicing and escapes genomic imprinting. Genomics (2005) 0.87
Rescue of the lethal scl(-/-) phenotype by the human SCL locus. Blood (2002) 0.86
The role of the stem cell leukemia (SCL) gene in hematopoietic and endothelial lineage specification. J Hematother Stem Cell Res (2002) 0.85
Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood (2012) 0.85
RFP represses transcriptional activation by bHLH transcription factors. Oncogene (2005) 0.85
Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions. J Clin Invest (2013) 0.85
Transcriptional link between blood and bone: the stem cell leukemia gene and its +19 stem cell enhancer are active in bone cells. Mol Cell Biol (2006) 0.83
Genomic imbalances in CML blast crisis: 8q24.12-q24.13 segment identified as a common region of over-representation. Genes Chromosomes Cancer (2003) 0.82